Chapter I. Pathogenesis

Get Permission
Rev Diabet Stud, 2012, 9(4):236-247 DOI 10.1900/RDS.2012.9.236

Metabolomics in the Studies of Islet Autoimmunity and Type 1 Diabetes

Matej Oresic

VTT Technical Research Centre of Finland, Tietotie 2, Espoo, FIN-02044 VTT, Finland

Manuscript submitted December 23, 2012; resubmitted January 21, 2013; accepted February 8, 2013.

Keywords: allostasis, autoimmunity, biomarker, lipid metabolism, lipidomics, metabolomics, systems biology


The metabolome is sensitive to genetic and environmental factors contributing to complex diseases such as type 1 diabetes (T1D). Metabolomics is the study of biochemical and physiological processes involving metabolites. It is therefore one of the key platforms for the discovery and study of pathophysiological phenomena leading to T1D and the development of T1D-associated complications. Although the application of metabolomics in T1D research is still rare, metabolomic research has already advanced across the full spectrum, from disease progression to the development of diabetic complications. Metabolomic studies in T1D have contributed to an improved etiopathogenic understanding and demonstrated their potential in the clinic. For example, metabolomic data from recent T1D studies suggest that a specific metabolic profile, or metabotype, precedes islet autoimmunity and the development of overt T1D. These early metabolic changes are attributed to many biochemical pathways, thus suggesting a systemic change in metabolism which may be inborn. Based on this evidence, the role of the metabolome in the progression to T1D is therefore to facilitate specific biochemical processes associated with T1D, and to contribute to the development of a vulnerable state in which disease is more likely to be triggered. This may have important implications for the understanding of T1D pathophysiology and early disease detection and prevention.

Fulltext: HTML , PDF (2.4 MB)

This article has been cited by other articles:

Metabolomics reveals new metabolic perturbations in children with type 1 diabetes

Galderisi A, Pirillo P, Moret V, Stocchero M, Gucciardi A, Perilongo G, Moretti C, Monciotti C, Giordano G, Baraldi E

Pediatr Diabetes 2017. In press

Tolerogenic Dendritic Cells from Poorly Compensated Type 1 Diabetes Patients Have Decreased Ability To Induce Stable Antigen-Specific T Cell Hyporesponsiveness and Generation of Suppressive Regulatory T Cells

Danova K, Grohova A, Strnadova P, Funda DP, Sumnik Z, Lebl J, Cinek O, Pruhova S, Kolouskova S, Obermannova B, Petruzelkova L, Sediva A, Fundova P, Buschard K, Spisek R, Palova-Jelinkova L

J Immunol 2017. 198(2):729-740

Mitochondrial aldehyde dehydrogenase 2 deficiency aggravates energy metabolism disturbance and diastolic dysfunction in diabetic mice

Wang C, Fan F, Cao Q, Shen C, Zhu H, Wang P, Zhao X, Sun X, Dong Z, Ma X, Liu X, Han S, Wu C, Zou Y, Hu K, Ge J, Sun A

J Mol Med (Berl) 2016. 94(11):1229-1240

Metabolomics applied to the pancreatic islet

Gooding JR, Jensen MV, Newgard CB

Arch Biochem Biophys 2016. 589:120-130

Modeling strategies to study metabolic pathways in progression to type 1 diabetes - Challenges and opportunities

Marinkovic T, Oresic M

Arch Biochem Biophys 2016. 589:131-137

Metabolomics in childhood diabetes

Frohnert BI, Rewers MJ

Pediatr Diabetes 2016. 17(1):3-14

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association

Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark A, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG

Diabetes Care 2015. 38(10):1964-1974

Heterogeneity in diabetes-associated autoantibodies and susceptibility to Type 1 diabetes: lessons for disease prevention

Ilonen J, Knip M, Vaarala O

Exp Rev Endocrinol Metab 2015. 10(1):25-34

Systems biology strategies to study lipidomes in health and disease

Hyötyläinen T, Oresic M

Prog Lipid Res 2014. 55:43-60